Novocure (NVCR) Tops Q4 EPS by 13c

Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $30.2 million versus the consensus estimate of $26.97 million.

There were 1,091 active patients on Optune at December 31, 2016, an increase of 486 active patients, or 80 percent, compared to December 31, 2015. The increase in active patients was driven both by prescription growth and by an increase in the percentage of newly diagnosed GBM patients who started Optune in prior periods and who typically have a longer duration of therapy. The portion of Optune prescriptions for newly diagnosed GBM was more than 55 percent in the fourth quarter 2016.

For earnings history and earnings-related data on Novocure (NVCR) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Methanex (MEOH) Tops Q1 EPS by 35c
• Alamos Gold (AGI) Misses Q1 EPS by 1c